It is not effective against emerging omicron subvariants, which is why it is no longer authorized for use in the U.S.
According to the FDA, bebtelovimab is not approved for use because it is not expected to counteract the BQ.1 and BQ. 1.1 subvariants. A majority of new infections in the US are caused by them.
The Health and Human Services Department is putting on hold pending requests for bebtelovimab, and the manufacturer has stopped distribution until further notice.
In the event that the Covid variant becomes dominant again in the future, bebtelovimab stocks should be on hand.
Bebtelovimab is a single-dose injection that can be given to people who catch Covid, but cannot take any other FDA-approved treatments. People with weak immune systems can't take Paxlovid with other drugs.
People with weak immune systems face a heightened risk from Covid this winter because of more immune evasive omicron subvariants.
The failure of Congress to pass additional Covid funding means that treatments will dwindle as new versions render them useless.
As the Pandemic went on, we hoped to expand our medicine cabinet. The medicine cabinet has shrunk because of the lack of Congressional funding.
President Joe Biden wants people with weak immune systems to talk to their doctors about what they should do to stay safe.
All Rights Reserved © 2024
